Show simple item record

dc.contributor.authorPowell, Marta K.
dc.contributor.authorCempírková, Dana
dc.contributor.authorDundr, Pavel
dc.contributor.authorGrimmichová, Tereza
dc.contributor.authorTřebický, Ferdinand
dc.contributor.authorBrown, Robert E.
dc.contributor.authorGregorová, Jana
dc.contributor.authorLitschmannová, Martina
dc.contributor.authorJanurová, Kateřina
dc.contributor.authorPešta, Michal
dc.contributor.authorHeneberg, Petr
dc.date.accessioned2020-03-25T23:32:29Z
dc.date.available2020-03-25T23:32:29Z
dc.date.issued2020
dc.identifier.citationTranslational Oncology. 2020, vol. 13, issue 2, p. 383-392.cs
dc.identifier.issn1936-5233
dc.identifier.urihttp://hdl.handle.net/10084/139363
dc.description.abstractBACKGROUND: Diabetes mellitus is unfavorably associated with cancer risk. The purpose of this multi-disciplinary project was to evaluate a possible association of diabetes mellitus and other comorbidities and their treatment with progression of colorectal cancer. PATIENTS AND METHODS: We investigated the correlation between pathological characteristics and clinical course, including comorbidities in 1004 Czech patients diagnosed and surgically treated for colorectal adenocarcinoma (CRC) between 1999 and 2016. RESULTS: In our data set, CRC patients treated with metformin due to coexisting diabetes mellitus type 2 (T2DM) developed fewer distant metastases which clinically correlates with slower CRC progression. Survival in metformin subgroup was longer, particularly in men with CRC. Osteoporosis may be a negative factor of survival in CRC patients. CONCLUSIONS: Our findings also indicate that aging, higher tumor grade and TNM stage, coexistence of selected endocrine disorders, and metabolic abnormalities may change the tumor microenvironment and impact survival in colorectal cancer, although mechanism of these observations yet to be explained. Patients with diabetes mellitus type 2 treated with metformin may represent the altered microenvironment with specifically tuned metabolic molecular responses and with various epigenetic characteristics. More awareness and increased understanding of the mechanisms underlying the positive effect of metformin on patients' survival could offer insight into new treatment methods and permit more individualized treatment plans.cs
dc.language.isoencs
dc.publisherElseviercs
dc.relation.ispartofseriesTranslational Oncologycs
dc.relation.urihttps://doi.org/10.1016/j.tranon.2019.10.011cs
dc.rights© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.cs
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/cs
dc.titleMetformin treatment for diabetes mellitus correlates with progression and survival in colorectal carcinomacs
dc.typearticlecs
dc.identifier.doi10.1016/j.tranon.2019.10.011
dc.rights.accessopenAccesscs
dc.type.versionpublishedVersioncs
dc.type.statusPeer-reviewedcs
dc.description.sourceWeb of Sciencecs
dc.description.volume13cs
dc.description.issue2cs
dc.description.lastpage392cs
dc.description.firstpage383cs
dc.identifier.wos000513932000029


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.
Except where otherwise noted, this item's license is described as © 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.